Data Disclosure Leads Researchers to End Study of Obesity Drug

NYT Health, 12 May 2015
Author: Andrew Pollack
“A study of an obesity drug has ended after the manufacturer released early and ultimately misleading data, researchers said on Tuesday. The company, Orexigen Therapeutics, disclosed in March that early results from a clinical trial of its drug Contrave had shown a 41 percent reduction in the risk of heart attacks, strokes and death from cardiovascular causes. Orexigen’s stock shot up, and the information no doubt helped lift sales of Contrave.”
Find article here.